In research that should help design radically new ways to treat cancer, British scientists at a recently opened cancer institute at Cambridge University have begun work that is pinpointing changes in cells many years before they develop into tumours.
The Early Cancer Institute – which has just received £11m from an anonymous donor – is focused on finding ways to tackle tumours before symptoms appear, reports The Guardian.
The research will exploit recent discoveries showing that many people develop precancerous conditions that lie in abeyance for long periods.
“The latency for a cancer to develop can go on for years, sometimes for a decade or two, before the condition abruptly manifests itself to patients,” said Professor Rebecca Fitzgerald, the institute’s director.
“Then doctors find they are struggling to treat a tumour which, by this stage, has spread through a patient’s body. We need a different approach, one that can detect a person at risk of cancer early on using tests that can be given to large numbers of people.”
One example of this is the cytosponge – a sponge on a string – which has been developed by Fitzgerald and her team. It is swallowed like a pill, expands in the stomach into a sponge, and is then pulled up the gullet collecting oesophagus cells on the way.
Those cells that contain a protein, called TFF3, and found only in precancerous cells, then provide an early warning that a patient is at risk of oesophageal cancer and needs monitoring. Crucially, this test can be administered simply and on a wide scale.
This contrasts with current approaches to other cancers, added Fitzgerald. “At present, we are detecting many cancers late and have to come up with medicines, which have become incrementally more expensive. We are often extending life by a few weeks at a cost of tens of thousands of pounds. We need to look at this from a different perspective.”
One approach being taken by the institute, which is to be renamed the Li Ka-shing Early Cancer Institute after the Hong Kong philanthropist who has supported other Cambridge cancer research, focuses on blood samples.
Provided by women as part of past screening services for ovarian cancer and kept in special stores, these samples have now been repurposed by the institute. “We have around 200 000 such samples and they are a goldmine,” said Jamie Blundell, a research group leader at the institute.
Using these samples, researchers have identified changes that differentiate those donors who have subsequently been diagnosed with a blood cancer 10 or even 20 years after they provided samples, from those who did not develop such conditions.
“We are finding clear genetic changes in a person’s blood more than a decade before they start showing symptoms of leukaemia,” said Blundell. “That shows there is a long window of opportunity you could use to intervene and give treatments that will reduce the odds of going on to get cancer.”
Cancers grow in stages and by spotting those with cells that have taken an early step on this ladder, it should be possible to block or hamper further developments.
A similar strategy is being taken by Harveer Dev, another group leader, who has investigated men who have had their prostates removed. His team is now developing biomarkers to provide better ways to pinpoint those who are likely to suffer poor outcomes from prostate cancer.
“Our pilot data suggest these tests may be better than existing PSA tests and will be crucial in spotting those those with prostate cancer that is likely to progress,” said Dev.
Pinpointing those at risk of cancer – for example, people from families who have an inherited predisposition to tumours – will form a key part of the institute’s strategy.
In addition, it will focus on finding ways to reduce cancer risks, as well as ensuring treatments can be widely administered.
See more from MedicalBrief archives:
NHS trials blood test to detect cancer before symptoms appear
New blood test for cancer up to 10x more sensitive
Cancer Alliance: R50bn needed for cancer over next decade
World-first: Saliva test detects a hidden throat cancer